Difference between revisions of "Tepotinib (Tepmetko)"
m |
m |
||
| Line 13: | Line 13: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *2/3/2021: Granted accelerated approval for adult patients with metastatic [[Non-small cell lung cancer|non-small cell lung cancer (NSCLC)]] harboring [[Biomarkers#MET|mesenchymal-epithelial transition (MET)]] [[Biomarkers#Exon_14|exon 14]] skipping alterations. | + | *2/3/2021: Granted accelerated approval for adult patients with metastatic [[Non-small cell lung cancer|non-small cell lung cancer (NSCLC)]] harboring [[Biomarkers#MET|mesenchymal-epithelial transition (MET)]] [[Biomarkers#Exon_14|exon 14]] skipping alterations. ''(Based on [https://clinicaltrials.gov/ct2/show/NCT02864992 VISION])'' |
==Also known as== | ==Also known as== | ||
| Line 25: | Line 25: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| + | [[Category:Mutation-specific medications]] | ||
[[Category:MET inhibitors]] | [[Category:MET inhibitors]] | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
[[Category:FDA approved in 2021]] | [[Category:FDA approved in 2021]] | ||
Revision as of 02:02, 21 April 2021
General information
Class/mechanism: C-Met inhibitor. Inappropriate or constitutive activation of the receptor tyrosine kinase c-Met and its signalling pathway is implicated in many cancers, playing a role in abnormal proliferation, survival, invasion, metastasis, and angiogenesis.
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Patient drug information
No information available.
Diseases for which it is used
History of changes in FDA indication
- 2/3/2021: Granted accelerated approval for adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations. (Based on VISION)
Also known as
- Code names: EMD-1214063, MSC-2156119, MSC-2156119J
- Brand name: Tepmetko